Company: CDT
Filing Date: 2025-06-09
Form Type: 8-K
Source: 0001641172-25-014322
Chunk: 3

Company: CDT Equity Inc.
Filing Date: 2025-06-09
Form: 8-K
Item: Item 3.02
Chunk 3
---
 revise and forward-looking statement contained herein, or to reflect any change in our expectations with regard thereto
or any other change in events, conditions, or circumstances on which any such statement is based, except to the extent otherwise required
by applicable law.

Item
9.01. Financial Statements and Exhibits.

(d)
Exhibits.

  Exhibit No.      Description                                            
         10.1      Joint Development Agreement, dated June 3, 2025        
         99.1      Press Release, dated June 4, 2025                      
 ──────────────────────────────────────────────────────────────────────────
          104      Cover Page Interactive Data File (embedded within the  

SIGNATURES

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

               CONDUIT PHARMACEUTICALS INC.                               
  June         By:                               /s/ Andrew               
               Name:                             Andrew Regan             
               Title:                            Chief Executive Officer